Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
Authors
Keywords
-
Journal
CANCER
Volume 121, Issue 11, Pages 1737-1746
Publisher
Wiley
Online
2014-10-26
DOI
10.1002/cncr.29082
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials
- (2014) Keith T Flaherty et al. LANCET ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Overall survival should be the primary endpoint in clinical trials for advanced non-small cell lung cancer
- (2013) P.K. Cheema et al. Current Oncology
- Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
- (2013) Thomas J. Herzog et al. GYNECOLOGIC ONCOLOGY
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- The current role and limitations of surrogate endpoints in advanced prostate cancer
- (2013) Leonard G. Gomella et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
- (2012) Ignacio Romero et al. ENDOCRINOLOGY
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
- (2012) Kelly L. Bolton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Progression-Free Survival: Meaningful or Simply Measurable?
- (2012) Christopher M. Booth et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer
- (2012) Katsuyuki Hotta et al. LUNG CANCER
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progression-free survival as a surrogate marker of overall survival
- (2011) Bernard Escudier CANCER
- Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?
- (2011) Eitan Amir et al. EUROPEAN JOURNAL OF CANCER
- A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer
- (2011) Sudha Sundar et al. GYNECOLOGIC ONCOLOGY
- Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
- (2011) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- (2010) M. Reck et al. ANNALS OF ONCOLOGY
- Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years
- (2010) Peter Iversen et al. BJU INTERNATIONAL
- Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy
- (2010) Daniel Y. C. Heng et al. CANCER
- Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions
- (2010) Alberto Ocaña et al. JOURNAL OF CLINICAL ONCOLOGY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
- (2009) E. D. Saad et al. ANNALS OF ONCOLOGY
- Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer
- (2009) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial
- (2009) Michael E. Ray et al. JNCI-Journal of the National Cancer Institute
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
- (2008) Tomasz Burzykowski et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now